Genetically Distinct and Clinically Relevant Classification of Hepatocellular Carcinoma: Putative Therapeutic Targets

Gastroenterology

Volumn 133, Issue 5, 2007, Pages 1475-1486

  Katoh, Hiroto ^a   Ojima, Hidenori ^a   Kokubu, Akiko ^a   Saito, Shigeru ^a   Kondo, Tadashi ^a   Kosuge, Tomoo ^b   Hosoda, Fumie ^a   Imoto, Issei ^c,d   Inazawa, Johji ^c,d   Hirohashi, Setsuo ^a   Shibata, Tatsuhiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d Japan Science and Technology Agency   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MYC PROTEIN; PROTEIN P53; RAPAMYCIN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CHROMOSOME NUMBER; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG INHIBITION; FEMALE; GENE AMPLIFICATION; GENE TARGETING; GENETIC ANALYSIS; GENOME; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KARYOTYPE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION; ONCOGENE C MYC; OUTCOME ASSESSMENT; PATHOLOGY; PRIORITY JOURNAL;

ADULT; AGED; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FINGERPRINTING; FEMALE; GENE DOSAGE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIGENE FAMILY; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35648950024     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.08.038     Document Type: Article

References (46)

1. Parkin D.M., Bray F., Ferlay J., et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. Tanaka Y., Hanada K., Mizokami M., et al. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 99 (2002) 15584-15589
3. Bruix J., Boix L., Sala M., et al. Focus on hepatocellular carcinoma. Cancer Cell 5 (2004) 215-219
4. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006) 674-687
5. Laurent-Puig P., and Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 25 (2006) 3778-3786
6. Thorgeirsson S.S., and Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31 (2002) 339-346
7. Lee J.S., Heo J., Libbrecht L., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12 (2006) 410-416
8. Lee J.S., Chu I.S., Heo J., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40 (2004) 667-676
9. Lee J.S., and Thorgeirsson S.S. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 127 (2004) S51-S55
10. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
11. Cappuzzo F., Bemis L., and Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354 (2006) 2619-2621
12. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
13. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
14. Katoh H., Shibata T., Kokubu A., et al. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol 43 (2005) 863-874
15. Midorikawa Y., Yamamoto S., Ishikawa S., et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene 25 (2006) 5581-5590
16. Okabe H., Ikai I., Matsuo K., et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology 31 (2000) 1073-1079
17. Kusano N., Okita K., Shirahashi H., et al. Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer 94 (2002) 746-751
18. Nishimura T., Nishida N., Itoh T., et al. Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss. Genes Chromosomes Cancer 35 (2002) 329-339
19. Hashimoto K., Mori N., Tamesa T., et al. Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 17 (2004) 617-622
20. Laurent-Puig P., Legoix P., Bluteau O., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120 (2001) 1763-1773
21. Poon T.C., Wong N., Lai P.B., et al. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 131 (2006) 1262-1270
22. Tanabe C., Aoyagi K., Sakiyama T., et al. Evaluation of a whole-genome amplification method based on adaptor-ligation PCR of randomly sheared genomic DNA. Genes Chromosomes Cancer 38 (2003) 168-176
23. Inazawa J., Inoue J., and Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 95 (2004) 559-563
24. Takada H., Imoto I., Tsuda H., et al. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 24 (2005) 8051-8060
25. Imoto I., Izumi H., Yokoi S., et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 66 (2006) 4617-4626
26. Shibata T., Uryu S., Kokubu A., et al. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 11 (2005) 6177-6185
27. Simes J.R. An improved Bonferroni procedure for multiple tests of significance. Biometrika 73 (1986) 751-754
28. Fisher R.A. Statistical methods for research workers. 11th ed. (1950), Oliver and Boyd, London
29. Kim G.J., Cho S.J., Won N.H., et al. Genomic imbalances in Korean hepatocellular carcinoma. Cancer Genet Cytogenet 142 (2003) 129-133
30. Pang A., Ng I.O., Fan S.T., et al. Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 146 (2003) 8-15
31. Sahin F., Kannangai R., Adegbola O., et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10 (2004) 8421-8425
32. Boyault S., Rickman D.S., de Reynies A., et al. Transcriptome classification of HCC is related to gene alterations and new therapeutic targets. Hepatology 45 (2007) 42-52
33. Shachaf C.M., Kopelman A.M., Arvanitis C., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431 (2004) 1112-1117
34. Calvisi D.F., Factor V.M., Ladu S., et al. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 126 (2004) 1374-1386
35. Thorgeirsson S.S., Lee J.S., and Grisham J.W. Functional genomics of hepatocellular carcinoma. Hepatology 43 (2006) S145-S150
36. Kondoh N., Wakatsuki T., Ryo A., et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 59 (1999) 4990-4996
37. Moon W.S., Rhyu K.H., Kang M.J., et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?. Mod Pathol 16 (2003) 552-557
38. Valdman A., Fang X., Pang S.T., et al. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60 (2004) 367-371
39. Kasugai Y., Tagawa H., Kameoka Y., et al. Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. Clin Cancer Res 11 (2005) 8265-8272
40. Fury M.G., Zahalsky A., Wong R., et al. A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 25 (2007) 165-172
41. Amino N., Ideyama Y., Yamano M., et al. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res 12 (2006) 1630-1638
42. McCarty M.F., Wey J., Stoeltzing O., et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3 (2004) 1041-1048
43. Jacobs M.D., Black J., Futer O., et al. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 280 (2005) 13728-13734
44. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6 (2006) 729-734
45. Katoh H., Shibata T., Kokubu A., et al. Epigenetic instability and chromosomal instability in hepatocellular carcinoma. Am J Pathol 168 (2006) 1375-1384
46. Momparler R.L. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin Oncol 32 (2005) 443-451